Literature DB >> 12443029

Preeclampsia: a multifactorial disease resulting from the interaction of the feto-maternal HLA genotype and HCMV infection.

M Carreiras1, S Montagnani, Z Layrisse.   

Abstract

PROBLEM: To clarify the possible influence of human leukocyte antigen (HLA) mother-child genotypes and human cytomegalo virus (HCMV) presence on the development of preeclampsia. METHODS OF STUDY: One hundred and four DNA samples from mothers with preeclampsia, mothers with a normal history of pregnancies and their neonates were tested by polymerase chain reaction-sequence specific oligonucleotide probes (PCR-SSOP) for HLA-A, -G, -DRB1, -DQA1, -DQB1 alleles. The HCMV sequences were analyzed using a PCR-SSOP method and the four primers described by Chou (Chou S: J Clin Microb 1992; 30:2307-2310).
RESULTS: Compared with their respective controls, a significant increase of DRB1*07 among neonates (P(c) = 0.05) and of DRB1*07 and/or DRB1*06 among pre-eclamptic mothers (P(c) = 0.003, RR = 8,5) was found. When HCMV sequences were detected in pre-eclamptic mothers carrying those phenotypes the RR increased up to 40. Furthermore, the fetal inheritance of a maternal HLA-G*0104 increased the risk for the appearance of the disease (RR = 30; P = 0.025).
CONCLUSION: The results suggest that the presence of alleles HLA-G*0104, DRB1*07/06, HCMV sequences and the fetal inheritance of maternal G*0104, should be considered as conditioning factors for the development of preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12443029     DOI: 10.1034/j.1600-0897.2002.01076.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  12 in total

1.  Cytomegalovirus infection in association with early onset pre-eclampsia.

Authors:  L Higgins; S Vause; C Tower
Journal:  BMJ Case Rep       Date:  2010-11-09

Review 2.  The etiology of preeclampsia.

Authors:  Eunjung Jung; Roberto Romero; Lami Yeo; Nardhy Gomez-Lopez; Piya Chaemsaithong; Adithep Jaovisidha; Francesca Gotsch; Offer Erez
Journal:  Am J Obstet Gynecol       Date:  2022-02       Impact factor: 8.661

Review 3.  Association between maternal infections and preeclampsia: a systematic review of epidemiologic studies.

Authors:  Luis O Rustveld; Sheryl F Kelsey; Ravi Sharma
Journal:  Matern Child Health J       Date:  2007-06-19

4.  Maternal and fetal human leukocyte antigen class Ia and II alleles in severe preeclampsia and eclampsia.

Authors:  J Emmery; R Hachmon; C W Pyo; W C Nelson; D E Geraghty; A M N Andersen; M Melbye; T V F Hviid
Journal:  Genes Immun       Date:  2016-04-28       Impact factor: 2.676

Review 5.  Pathogenesis of preeclampsia: the genetic component.

Authors:  Francisco J Valenzuela; Alejandra Pérez-Sepúlveda; María J Torres; Paula Correa; Gabriela M Repetto; Sebastián E Illanes
Journal:  J Pregnancy       Date:  2011-12-01

Review 6.  HLA Class Ib Molecules and Immune Cells in Pregnancy and Preeclampsia.

Authors:  Snezana Djurisic; Thomas Vauvert F Hviid
Journal:  Front Immunol       Date:  2014-12-23       Impact factor: 7.561

7.  Large scale aggregate microarray analysis reveals three distinct molecular subclasses of human preeclampsia.

Authors:  Katherine Leavey; Shannon A Bainbridge; Brian J Cox
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

Review 8.  A Dormant Microbial Component in the Development of Preeclampsia.

Authors:  Douglas B Kell; Louise C Kenny
Journal:  Front Med (Lausanne)       Date:  2016-11-29

9.  Protective Role of Maternal P.VAL158MET Catechol-O-Methyltransferase Polymorphism against Early-Onset Preeclampsia and its Complications.

Authors:  Tijana Krnjeta; Ljiljana Mirković; Svetlana Ignjatović; Dragana Tomašević; Jelena Lukić; Drina Topalov; Ivan Soldatović; Nada Majkić-Singh
Journal:  J Med Biochem       Date:  2016-07-06       Impact factor: 3.402

Review 10.  The many faces of human leukocyte antigen-G: relevance to the fate of pregnancy.

Authors:  Mette Dahl; Snezana Djurisic; Thomas Vauvert F Hviid
Journal:  J Immunol Res       Date:  2014-03-04       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.